Montefiore Hospital

Other

Abbott Laboratories Corporation

University of Pittsburgh

Montefiore Hospital Association of Western Pennsylvania

Montefiore - University Hospital

The Montefiore Hospital Society of Western Pennsylvania, Inc.

Ronald T Stanko

Robert H Miller

Mark Anthony McCamish

Treating mammals having ischemic bowel with a therapeutic quantity of pyruvate enterally or parenterally will retard neutrophil infiltration and retain morphology during and following the bowel ischemia. The pyruvate is introduced into the patient enterally or parenterally during the bowel ischemia or the succeeding bowel reperfusion and, preferably, prior to the bowel ischemia. The pyruvate dosage is from 1% to 20% by weight of the patient's caloric intake.

Retarding neutrophil infiltration ad morphologic reduction in ischemic

Growth of an adenocarcinoma in the liver, lung, lymph node or mammary tissue in a mammal can be inhibited by orally administering a therapeutically effective dosage of pyruvate in the form of sodium pyruvate, calcium pyruvate or organic esters of pyruvate. The pyruvate treatment also retards the development of breaks in the DNA strands associated with the malignancy.

Inhibiting growth and spread of malignancy and retarding DNA breaks

Growth of mammary adenocarcinoma in a mammal can be inhibited by orally administering a therapeutically effective dosage of pyruvate in the form of sodium pyruvate, calcium pyruvate or organic esters of pyruvate or precursors of pyruvate.

Inhibiting growth of mammary adenocarcinoma

A therapeutic method is provided to reduce ischemia/reperfusion injury to the heart muscle by perfusing pyruvylglycine into the circulatory system of a patient who has had a heart attack or suffered coronary occlusion.

Use of pyruvylglycine to treat ischemia/reperfusion injury following

Certain incidents in mammals trigger the generation of free-radicals which are associated with cell death. Animals experiencing such medical incidents are dosed with pyruvate salts or esters in an amount of 5 to 20 weight percent of the total carbohydrate intake. The dosage of pyruvate may be provided to the animal before the medical incident, during the medical incident and after the medical incident. In addition to the known property in pyruvate for scavenging free-radicals, this disclosure points out the unexpected effectiveness of pyruvate as an inhibitor of free-radical generation.

Method for inhibiting generation of free-radicals

A method for treating a medical patient prior to or during heart trauma, e.g., myocardial infarction, angina and ischemia. An effective dosage of pyruvate is introduced into the patient to increase the patient's cardiac output and stroke volume, to decrease the patient's heart rate and to reduce the oxygen demand of the patient's heart. The dosage may be introduced intravenously into the patient or orally as a component of the patient's diet. The oral feeding method is especially useful for surgical patients prior to surgical procedures which are likely to encourage cardiac trauma and useful for patients exhibiting symptoms of chronic congestive heart failure.

Method for treating a medical patient for cardiac trauma

A process for lowering the blood cholesterol of hyperlipidemic patients by oral ingestion of pyruvate and a confection (cereal bar, fruit bar, candy) containing pyruvate as the ingestion medium.

Method for lowering high blood cholesterol levels in hyperlipidemic

A method for treating animals having diabetic tendencies to improve the glucose metabolism of the animal by oral administration of therapeutically effective amounts of pyruvate and dihydroxyacetone. The treatment lowers Glucose Tolerance Test Values and lowers Fasting Blood Glucose Test values.

Method for improving the glucose metabolism of an animal having diabetic

A method for reducing the weight gain in an animal by orally administering ver a prolonged period a therapeutically effective amount of dihydroxyacetone to which may be added riboflavin. The method also includes administering dihydroxyacetone and/or pyruvate in therapeutically effective amounts to increase the glycogen store in the liver.

Method for preventing body fat deposition in mammals

A method for reducing body fat deposition in non-mammals such as chickens by orally administering over a prolonged period a therapeutic mixture of effective amounts of pyruvate and dihydroxyacetone to which may be added riboflavin. The method also increases the total body protein of the non-mammal.

Method for preventing body fat deposition in animals

A method for reducing the weight gain in mammals by orally administering over a prolonged period therapeutically effective amounts of pyruvate to which may be added riboflavin. The method also has the effect of increasing the body protein concentration.

A method for reducing the rate of liver triglyceride synthesis and body fat deposition in mammals by orally administering over a prolonged period a therapeutic mixture of effective amounts of pyruvate and dihydroxyacetone to which may be added riboflavin. The method also has the effect of increasing the glycogen-storing capabilities of the liver and increasing the body protein concentration.

A method for reducing the rate of liver triglyceride synthesis and body fat deposition in mammals by orally administering over a prolonged period a therapeutic mixture of effective amounts of pyruvate and dihydroxyacetone to which may be added riboflavin. The method also has the effect of increasing the glycogen-storing capabilities of the liver.

A method is provided for preventing the accumulation of fatty deposits in mammalian livers due to ingestion of alcohol. The method consists of administering a suitable dosage of a mixture of pyruvate and dihydroxyacetone to which riboflavin may also be added.

Growing community of inventors

Pittsburgh, PA, United States of America

Ronald T Stanko